Synmosa Biopharma (4114) - Total Liabilities

Latest as of December 2025: NT$3.89 Billion TWD ≈ $122.43 Million USD

Based on the latest financial reports, Synmosa Biopharma (4114) has total liabilities worth NT$3.89 Billion TWD (≈ $122.43 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Synmosa Biopharma - Total Liabilities Trend (2015–2025)

This chart illustrates how Synmosa Biopharma's total liabilities have evolved over time, based on quarterly financial data. See 4114 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Synmosa Biopharma Competitors by Total Liabilities

The table below lists competitors of Synmosa Biopharma ranked by their total liabilities.

Company	Country	Total Liabilities
Skjern Bank A/S CO:SKJE	Denmark	Dkr13.79 Billion
B&S Group SA AS:BSGR	Netherlands	€699.29 Million
ION Exchange (India) Limited NSE:IONEXCHANG	India	Rs20.40 Billion
Solowin Holdings Ordinary Share NASDAQ:SWIN	USA	$7.58 Million
Shanghai Titan Scientific Co. Ltd. A SHG:688133	China	CN¥2.07 Billion
HANGZHOU TIGERMED CO. H 1 F:5HZ1	Germany	€4.24 Billion
Jiangsu Hengxing New Material SHG:603276	China	CN¥124.51 Million
Zhejiang Extek Technology Co. Ltd. A SHE:301399	China	CN¥170.66 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Synmosa Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4114 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.95	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.44	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Synmosa Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Synmosa Biopharma (2015–2025)

The table below shows the annual total liabilities of Synmosa Biopharma from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$3.89 Billion ≈ $122.43 Million	-0.49%
2024-12-31	NT$3.91 Billion ≈ $123.04 Million	+7.65%
2023-12-31	NT$3.63 Billion ≈ $114.29 Million	-20.34%
2022-12-31	NT$4.55 Billion ≈ $143.47 Million	+7.87%
2021-12-31	NT$4.22 Billion ≈ $133.00 Million	-4.55%
2020-12-31	NT$4.42 Billion ≈ $139.34 Million	+12.91%
2019-12-31	NT$3.92 Billion ≈ $123.41 Million	+28.03%
2018-12-31	NT$3.06 Billion ≈ $96.39 Million	-13.54%
2017-12-31	NT$3.54 Billion ≈ $111.48 Million	+45.22%
2016-12-31	NT$2.44 Billion ≈ $76.77 Million	+54.36%
2015-12-31	NT$1.58 Billion ≈ $49.73 Million	--

About Synmosa Biopharma

TWO:4114 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$492.35 Million

NT$15.63 Billion TWD

Market Cap Rank

#12445 Global

#478 in Taiwan

Share Price

NT$30.95

Change (1 day)

+0.49%

52-Week Range

NT$30.05 - NT$39.25

All Time High

NT$6197.22